



9<sup>th</sup> February, 2017

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01023	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001
<b>Symbol : AMRUTANJAN</b>	<b>Scrip Code: 590006</b>

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting – Regulation 33 read with Clause 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)**

Pursuant to the above regulation, we wish to inform that the Board of Directors of the Company at its meeting held today (9<sup>th</sup> February, 2017) had inter-alia:

- Approved the Un-audited Standalone Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2016, as recommended by the audit committee at its meeting held today (9<sup>th</sup> February, 2017). The same along with the Limited Review Report issued by the P.S.Subramania Iyer & Co , Chartered Accountants; Statutory Auditors of the Company is enclosed;
- Declared 2<sup>nd</sup> Interim Dividend of Rs. 1.10/- per share for the year 2016-2017 on the Equity Shares of the Company.
- Approved the modified/ altered Scheme of merger of the Wholly Owned Subsidiary, M/s. Amrutanjan Pharmaessense Private Limited with M/s. Amrutanjan Health Care Limited.

The Board Meeting commenced at 11.15 A.M. and concluded at 2: 15 P.M

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Amrutanjan Health Care Limited



(M Srinivasan)  
Company Secretary & Compliance Officer

**Encl:**

- Un- audited Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2016
- Limited Review Report for the quarter and nine months ended 31<sup>st</sup> December, 2016
- Highlights

**Amrutanjan Health Care Limited**

103, (Old No. 42-45), Luz Church Road,  
Mylapore, Chennai - 600 004  
Tamil Nadu, India.  
Tel : +91-44-24994465 / 4165 / 4164 / 4366  
Fax : +91 - 44 - 24994585

E-mail : [customercare@amrutanjan.com](mailto:customercare@amrutanjan.com)  
Web Site : [www.amrutanjan.com](http://www.amrutanjan.com)  
Toll Free No. : 1 - 800 - 425 - 4545  
CIN - L24231TN1936PLC000017

## AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.

email id : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No : L24231TN1936PLC000017  
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DEC 2016

(Rs. In Lakhs)

Sl No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
		(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Audited)
	<b>PART - I</b>						
	Gross Sales	6,182.54	5,772.68	5,582.81	15,555.82	13,288.98	19,192.25
	Less : Excise Duty	313.34	295.28	254.93	768.72	615.51	882.33
1.	(a) Net Sales / Income from operations	5,869.20	5,477.40	5,327.88	14,787.10	12,673.47	18,309.92
	(b) Other Operating Income	56.58	43.46	26.76	127.52	95.33	127.76
	<b>Total Income</b>	<b>5,925.78</b>	<b>5,520.86</b>	<b>5,354.64</b>	<b>14,914.62</b>	<b>12,768.80</b>	<b>18,437.68</b>
2.	<b>Expenditure</b>						
a.	(Increase) / Decrease in Stock in Trade and work in progress	20.02	(97.39)	105.11	(404.61)	(114.91)	33.67
b.	Consumption of raw & other materials	1,682.55	1,720.29	1,503.15	4,992.85	4,060.85	5,858.90
c.	Purchase of Traded goods	273.70	259.79	97.50	811.80	424.08	626.80
d.	Employee Cost	975.87	762.92	803.70	2,522.09	2,114.86	2,801.22
e.	Advertisement & Selling Expenditure	1,295.51	903.41	1,028.45	2,467.10	2,085.04	2,967.19
f.	Depreciation	34.60	59.41	69.37	157.03	181.41	252.46
g.	Other Expenditure	767.35	832.76	676.85	2,218.06	1,910.82	2,987.89
	<b>Total Expenditure</b>	<b>5,049.60</b>	<b>4,441.19</b>	<b>4,284.13</b>	<b>12,764.32</b>	<b>10,662.15</b>	<b>15,528.13</b>
3.	<b>Profit from Operations before Other Income, Interest and Exceptional Items (1 - 2)</b>	<b>876.18</b>	<b>1,079.67</b>	<b>1,070.51</b>	<b>2,150.30</b>	<b>2,106.65</b>	<b>2,909.55</b>
4.	Other Income	115.85	112.60	103.38	342.04	403.95	554.80
5.	<b>Profit before Interest and Exceptional Items (3 + 4)</b>	<b>992.03</b>	<b>1,192.27</b>	<b>1,173.89</b>	<b>2,492.34</b>	<b>2,510.60</b>	<b>3,464.35</b>
6.	Interest	0.17	3.14	2.45	8.83	6.37	8.16
7.	<b>Profit after Interest but before Exceptional Items (5 - 6)</b>	<b>991.86</b>	<b>1,189.13</b>	<b>1,171.44</b>	<b>2,483.51</b>	<b>2,504.23</b>	<b>3,456.19</b>
8.	Exceptional items	236.39	-	-	236.39	-	-
9.	<b>Profit from Ordinary Activities before Tax (7 + 8)</b>	<b>1,228.25</b>	<b>1,189.13</b>	<b>1,171.44</b>	<b>2,719.90</b>	<b>2,504.23</b>	<b>3,456.19</b>
10.	Tax Expense incl Deferred Tax	263.33	394.55	303.09	749.83	733.00	1,214.41
11.	<b>Net Profit from Ordinary Activities after Tax (9 - 10)</b>	<b>964.92</b>	<b>794.58</b>	<b>868.35</b>	<b>1,970.07</b>	<b>1,771.23</b>	<b>2,241.78</b>
12.	Extraordinary Items :	-	-	-	-	-	-
13.	<b>Net Profit for the Period (11 + 12)</b>	<b>964.92</b>	<b>794.58</b>	<b>868.35</b>	<b>1,970.07</b>	<b>1,771.23</b>	<b>2,241.78</b>
14.	Paid-up Equity Share Capital (Face Value Rs.2 /- (Rs. 2/- each)	292.31	292.31	292.31	292.31	292.31	292.31
15.	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	11,755.46
16.	<b>Earnings Per Share EPS - Rs. (Not Annualised)</b>						
	a) Basic and diluted EPS before Extraordinary items (Rs.)	6.60	5.44	5.94	13.48	12.12	15.34
	b) Basic and diluted EPS after Extraordinary items (Rs.)	6.60	5.44	5.94	13.48	12.12	15.34

**Notes**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its Meeting held on 9th February, 2017
2. The statutory auditors have carried out a limited review of the above financial results.
3. Exceptional Item represents refund of Excise Duty (net of expenses) paid in the earlier years, received during the year.
4. The figures for the previous quarter / period have been regrouped / reclassified wherever necessary.

For Amrutanjan Health Care Limited



S. Sambhu Prasad  
Chairman & Managing Director

Place : Chennai  
Date : 9th Feb 2017



# AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45), LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.

email id : investors@amrutanjan.com; website : www.amrutanjan.com; CIN No : L24231TN1936PLC000017

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DEC 2016**

(Rs. In Lakhs)

## Segmentwise Revenue, Results and Capital Employed

Particulars	STANDALONE					
	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Audited)
<b>1 Segment Revenue</b>						
Net Sales						
a) O T C Products	5,565.17	5,138.28	5,149.30	13,257.12	11,399.38	16,138.50
b) Beverages	304.03	339.12	178.58	1,529.98	1,274.09	2,171.42
c) APMC	56.58	43.46	26.76	127.52	95.33	127.76
<b>T o t a l</b>	<b>5,925.78</b>	<b>5,520.86</b>	<b>5,354.64</b>	<b>14,914.62</b>	<b>12,768.80</b>	<b>18,437.68</b>
Less: Inter segment revenue	-	-	-	-	-	-
<b>Sales / Income from operations</b>	<b>5,925.78</b>	<b>5,520.86</b>	<b>5,354.64</b>	<b>14,914.62</b>	<b>12,768.80</b>	<b>18,437.68</b>
<b>2 Segment Results</b>						
Profit/(Loss) Before Tax and Interest						
a) O T C Products	1,016.71	1,323.21	1,243.77	2,695.11	2,590.10	3,542.32
b) Beverages	(109.20)	(128.69)	(77.46)	(352.27)	(170.35)	(245.74)
c) APMC	(19.95)	(56.93)	(55.14)	(109.36)	(133.33)	(165.55)
<b>T o t a l</b>	<b>887.56</b>	<b>1,137.59</b>	<b>1,111.17</b>	<b>2,233.48</b>	<b>2,286.42</b>	<b>3,131.03</b>
Less: i) Interest	0.17	3.14	2.45	8.83	6.37	8.16
ii) Other un-allocable expenditure net off unallocable income	(104.47)	(54.68)	(62.72)	(258.86)	(224.18)	(333.32)
Less: Exceptional items	(236.39)	-	-	(236.39)	-	-
Add: Extraordinary Items	-	-	-	-	-	-
<b>Total Profit Before Tax</b>	<b>1,228.25</b>	<b>1,189.13</b>	<b>1,171.44</b>	<b>2,719.90</b>	<b>2,504.23</b>	<b>3,456.19</b>
<b>3 Segment Assets</b>						
a) O T C Products	10,211.86	9,211.69	8,469.44	10,211.86	8,469.44	8,358.16
b) Beverages	1,864.92	1,641.97	1,536.13	1,864.92	1,536.13	1,357.39
c) APMC	32.72	33.58	36.20	32.72	36.20	35.90
d) Unallocated	4,680.82	5,052.65	4,942.83	4,680.82	4,942.83	5,122.08
<b>Total</b>	<b>16,790.32</b>	<b>15,939.89</b>	<b>14,984.60</b>	<b>16,790.32</b>	<b>14,984.60</b>	<b>14,873.53</b>
<b>4 Segment Liabilities</b>						
a) O T C Products	2,419.49	2,096.66	2,267.53	2,419.49	2,267.53	1,949.10
b) Beverages	509.51	427.40	365.69	509.51	365.69	541.20
c) APMC	-	-	-	-	-	-
d) Unallocated	36.97	362.91	306.73	36.97	306.73	335.46
<b>Total</b>	<b>2,965.97</b>	<b>2,886.97</b>	<b>2,939.95</b>	<b>2,965.97</b>	<b>2,939.95</b>	<b>2,825.76</b>



For Amrutanjan Health Care Limited

*S. Sambhu Prasad*

**S. Sambhu Prasad**  
Chairman & Managing Director

Place : Chennai  
Date : 9th Feb 2017



# P. S. SUBRAMANIA IYER & CO.

CHARTERED ACCOUNTANTS

New No. 103, (Old No. 57/2), P. S. Sivasamy Salai, (Sullivan Garden Road), Mylapore, Chennai - 600 004.

Phone : 2499 2449 / 2499 2470

E-mail : pssco\_2000@yahoo.com pssandco@gmail.com

## LIMITED REVIEW REPORT

**The Board of Directors,  
Amrutanjan Health Care Limited,  
New No.103 Luz Church Road,  
Chennai-600004.**

We have reviewed the accompanying statement of unaudited financial results of Amrutanjan Health Care Limited ("the Company") for the period ended 31<sup>st</sup> December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Engagements to Review Financial statements" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financials statements are free of material misstatement. A review is limited primarily to enquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements)Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For P.S.Subramania Iyer & Co.,  
Chartered Accountants  
Firm Registration No : 004104S**



*V Swaminathan*

**V.Swaminathan  
Partner**

**Membership No : 22276**

Place : Chennai  
Date : 09/02/2017

(Our Bank Details : State Bank of Mysore, Branch Abhiramapuram, Current A/c. No. 54008541474  
IFS Code : SBMY0040203 - HDFC Bank, Branch R.A. Puram, Current A/c. No. 01412000002912  
IFSC Code : HDFC0000141 - Service Tax Regn. No. AAAFP3234H ST001 - PAN : AAAFP3234 H)

## Highlights of YTD Dec 2016 and Q3 results

### YTD Dec 2016

- Gross sales have increased from Rs. 133.95 cr. To Rs. 156.96 Cr. ( 17.17% Growth )
- Profit Before Tax has increased from Rs. 25.04 Cr. to Rs. 27.19 Cr. ( 9 % increase)
- Profit after Tax has increased from Rs. 17.71 Cr to Rs. 19.70 Cr. ( 11 % increase )
- Earnings per share has gone up from 12.12 of last year to 13.48 ( 11 % increase )

### OTC Division

- Gross sales of OTC have increased from Rs. 120.03 cr. To Rs. 140.12 Cr.  
( 16.74% Growth out of which volume growth is 13.54 % )
- Volume of 523.95 Tons. Sold during Apr-Dec of 2016-17 as against 459.33 Tons during Apr –Dec of 2015-16.

### Fruitnik Division

- Gross Sales increased from Rs. 12.96 Cr. to Rs. 15.57 Cr. for YTD Dec ( 20.14 % increase over last year same period )
- The margin is affected due to increase in the cost of Raw materials, advertisements and the employee cost.
- ATL Spends have been increased from Rs. 31 Lakhs to Rs. 93 lakhs.

### Q3 Performance

- Gross Sales of OTC increased from Rs. 54.04 Cr. to Rs. 58.76 Cr. for YTD Dec ( 9 % increase over last year same period )
- Gross Sales of F & B divn. increased from Rs. 1.82 Cr. to Rs. 3.11 Cr. for YTD Dec ( 72 % increase over last year same period )
- Revenue in Pain management Centre for Q3 is Rs. 52.69 lakhs as against Rs. 26.76 Lakhs during Q3 of 2015-16.

## The salient point of the Outcome of the Board Meeting

The Company have been paying dividend twice a year so far and It has been decided to distribute the dividend across the year paying interim dividend more than once preferably every quarter. It has been decided to pay Rs. 1.10 per share of face value Rs. 2.00 as second interim dividend with the book closure date as 17<sup>th</sup> February 2017.

